Literature DB >> 6861639

Use of anticholinergics in the nursing home: an empirical study and review.

R Seifert, J Jamieson, R Gardner.   

Abstract

The Medicare Utilization Review Committee conducted a survey to determine the use of drugs with anticholinergic effects in confused elderly nursing home patients. Twenty-nine patients (34.5 percent) were receiving anticholinergic drugs, predominantly from the antidepressant and antipsychotic class. Thioridazine (Mellaril) was the most frequently used antipsychotic. No patients received higher than the equivalent recommended daily dose of atropine when calculated in terms of relative anticholinergic potency. No statistically significant correlation could be found between the presence of confusion and the amount of anticholinergics administered. Confusion and cognitive deterioration frequently are encountered when caring for aged patients. Clinical experience and recent studies suggest that anticholinergics may increase the risk of or exacerbate existing confusion, and this possible effect of anticholinergic activity should be considered when prescribing for elderly patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861639     DOI: 10.1177/106002808301700618

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  3 in total

1.  Prevalence and predictors of anticholinergic medication use in elderly nursing home residents with dementia: analysis of data from the 2004 National Nursing Home Survey.

Authors:  Satabdi Chatterjee; Sandhya Mehta; Jeffrey T Sherer; Rajender R Aparasu
Journal:  Drugs Aging       Date:  2010-12-01       Impact factor: 3.923

2.  The relationship between anticholinergic medications and Mini-Cog scores in older adults receiving home health care.

Authors:  Susan L Lakey; Peggy S Odegard; Travis E Sonnett; Stephen M Setter; Soo Borson
Journal:  Consult Pharm       Date:  2009-09

3.  Central Anticholinergic Adverse Effects and Their Measurement.

Authors:  Pasi Lampela; Teemu Paajanen; Sirpa Hartikainen; Risto Huupponen
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.